The Efficacy of Venlafaxine and Duloxetine in Improving Chemotherapy-Induced Neurotoxicity
Not Applicable
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy.
- Registration Number
- IRCT20230201057300N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Age 18 to 75 years
Incidence of Neuropathy after starting Chemotherapy
Cancer Diagnosis
Receive Chemotherapy
Exclusion Criteria
Having an Underlying Neuropathy Disease such as Diabetes Mellitus
Incomplete Treatment
Intolerance of the patient due to Drug side effects
Death of Patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Peripheral Neuropathy. Timepoint: Severity of Peripheral Neuropathy at the Beginning of the study then weekly. Method of measurement: NCI- Common Terminology Criteria for Adverse Event- ver3.
- Secondary Outcome Measures
Name Time Method